Abstract 4738
Background
As survival seems to be equal after either stereotactic body radiotherapy (SBRT) or surgery for patients with stage I non-small cell lung cancer (NSCLC), treatment impact on the quality of life (QoL) after is essential for well-informed decision making. After a surgical resection, deterioration of QoL is often observed in the early post-treatment period, whereas QoL is reported to be maintained after SBRT. The aim of this study is to compare QoL in the first year after SBRT and surgery.
Methods
QoL was assessed by using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) and the lung cancer-specific supplementary questionnaire (QLQ-LC13) at baseline and 3, 6 and 12 months after treatment. Two prospectively collected databases of patients with clinically proven stage I NSCLC, from two large hospitals in the Netherlands, were pooled (n = 306; 256 patients were treated with SBRT and 41 patients with surgery). This observational study design is susceptible to selection bias. To correct for confounding, propensity-scores were calculated using forward stepwise logistic regression, to be selected for surgical treatment. For the final model, age, dichotomized ECOG score and FEV1% predicted scores were selected.
Results
The 41 surgical patients were matched to 41 SBRT patients on propensity score with a 1:1 ratio. At baseline, patients in the surgery group report a lower health related-QoL compared to patients in the SBRT group. However, during the first year after treatment, no clinical meaningful differences in social-, role, physical, emotional and cognitive domains were observed between patients treated using either modality. Furthermore, no clinical meaningful differences in QLQ-LC13 scores (dyspnea, pain, fatigue) after treatment were observed.
Conclusions
This study comparing a matched cohort, revealed no clinical significant differences in QoL following either SBRT or surgery for an early stage NSCLC.
Clinical trial identification
Legal entity responsible for the study
Leonie Alberts and Harold Wolff.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
H.B. Wolff, V.M.H. Coupe: Research funding: Novartis. Novartis Pharma B.V. was not involved in the data collection, data analysis, or reporting. F.J. Lagerwaard: Honoraria, Speaker's bureau: Viewray inc USA. S. Senan: Honoraria, Consulting/advisory role company: Lilly Oncology, AstraZeneca; Research funding: Varian Medical systems. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract